What's behind Ionis Pharmaceuticals's latest 3.5% stock pullback?

What's behind Ionis Pharmaceuticals's latest 3.5% stock pullback?
Ionis slides 3.45% today to $51.44

Ionis Pharmaceuticals, Inc. (IONS) fell 3.45% after reporting a second-quarter adjusted loss and disappointing clinical trial results for its lead pipeline candidate. The move is reinforced by broad technical weakness, with the stock lingering below all major moving averages and immediate support threatened.

IONS price prediction
24H 0.95%
$27.65
48H 1.64%
$27.84
7D 1.57%
$27.82
1M -50.6%
$13.53
3M -46.55%
$14.64
6M -49.58%
$13.81
12M -70.46%
$8.09
Current price: $27.39 0.4650 1.73%
Closed 11/18
Daily range 26.70 Arrow from to Icon 28.04
Weekly range 26.55 Arrow from to Icon 29.90
Loading...

Highlights

  • Ionis Pharmaceuticals reported a Q2 2026 adjusted loss per share of $0.43, reversing from the prior year's $0.86 profit.
  • FDA review for zilganersen in Alexander disease remains in progress with a decision anticipated by September, while the phase III Wainua trial failed its main efficacy goal.
  • Shares are under strong bearish pressure and technical indicators signal a high probability of continued downside, with expected trading between $49.22 and $53.66 over the next week.

Earnings miss and trial failure sharpen investor uncertainty

Ionis Pharmaceuticals reported second-quarter 2026 adjusted losses per share of $0.43, compared to adjusted earnings of $0.86 in the prior year. The company recorded Q2 revenue of $268 million and maintained a cash balance of $2.1 billion to support its drug development pipeline. A regulatory filing for FDA approval of zilganersen in Alexander disease remains under review, with a decision expected by September. The phase III CARDIO-TTRansform trial for Wainua in hereditary TTR amyloidosis, conducted with AstraZeneca, did not meet its primary endpoint.

Anton Kharitonov, expert at Traders Union, sees Ionis Pharmaceuticals under clear pressure after a steep quarterly loss and failure in a key clinical trial. He notes that the technical picture remains firmly bearish, with the stock well below its MA-20, MA-50, and MA-200. Weak momentum is confirmed by the oversold RSI and negative MACD, as well as heightened volatility and a downside gap. Kharitonov highlights persistent negative sentiment, reinforced by missed expectations and a lack of immediate positive catalysts. "Based on the critical confluence of weak fundamentals and strong technical selling, I see a high risk of further declines in the near term."
Viktoras Karapetjanc, expert at Traders Union, sees opportunity despite Ionis’s recent setbacks. He points to the company’s $2.1 billion cash buffer and a pending FDA decision as fundamentals that can re-ignite momentum. Karapetjanc views the current pullback as a setup for longer-term investors, noting Ionis’s capacity to fund its pipeline and weather setbacks. He remains confident that, with strong financing and multiple shots on goal, the bullish structure for Ionis remains intact. "I expect renewed upside once the market digests news and shifts focus toward future regulatory milestones."
Jainam Mehta, market strategist, notes that IONS is in a pronounced downtrend, with momentum skewed to the downside. He highlights the immediate volatility band between $49.22 and $53.66 and sees any move beyond this range as decisive. He suggests that extremely oversold readings could trigger a short-term contrarian bounce if volume dries up. "If the stock fails to hold above $49.22, I’d consider tactical shorts, but a breakout above $53.66 could force a quick reversal for nimble traders."
Ionis Pharmaceuticals asset chart
Ionis Pharmaceuticals price dynamics. Source: TradingView.

Persistent downtrend as major supports and indicators align bearish

IONS remains under all major moving averages, trading below the MA-20 at $61.25, MA-50 at $69.89, and MA-200 at $75.26, signaling persistent bearish pressure across all timeframes. Near-term levels are defined by a ceiling at $52.65 and a floor at $51.43. Technical indicators show a strong negative bias: MACD signals a strong sell, ADX confirms a pronounced downtrend, RSI is oversold at 28.24, and CCI stands at -57.23. Both Stochastic RSI and Bull/Bear Power indicate that sellers dominate, with BBP also in oversold territory. The stock closed near session lows, experiencing heightened intraday volatility following a downside gap at the open.

Previously it was reported that Ionis Pharmaceuticals faced a significant setback and sustained bearish momentum following disappointing late-stage clinical trial results for Wainua. The current technical setup reinforces this negative outlook, with persistent downside pressure suggesting traders should monitor for a potential break below $49.22 as the next material risk.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.